Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.
Meati, also known as Emergy Foods, is a consumer goods company based in Boulder, Colorado, founded in 2016. The company specializes in producing whole muscle, nutritious plant-based meats designed to promote healthier lifestyles and environmental sustainability. By utilizing proprietary, clean technologies, Meati offers nutrient-dense meat alternatives that aim to appeal to a wide audience, ensuring that consumers can enjoy meals that are both good for their health and the planet.
Course Hero, Inc. is an online learning platform that offers a wide range of study resources for students and educators. Founded in 2006 and based in Redwood City, California, the platform provides access to an extensive database of student-uploaded materials, including lecture notes, study guides, practice problems, exams, and video lectures from various educational institutions. Course Hero operates on a free and subscription model, allowing users to unlock additional study tools and resources tailored to numerous subjects, from economics to literature. The platform also features an educator component for distributing and publishing materials, and offers a flashcards application for personalized studying. Additionally, students can access expert tutors for assistance with their academic inquiries.
SaltPay is a FinTech company dedicated to building a better future for merchants by servicing them through payment and management tools. Focused on efficiency, technology, and people, they give merchants the help they need to grow.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
Sundae operates a home-selling platform designed to assist homeowners in selling houses that are outdated or in need of repairs. The company addresses the challenges faced by sellers in a traditional real estate market, where local investors often exploit homeowner distress to acquire properties at low prices. Sundae aims to provide a better outcome for these sellers by offering competitive off-market prices without the need for cleanup, repairs, or showings. Through a data-driven model, Sundae anticipates when homeowners may require assistance and employs a skilled sales and marketing team to effectively reach them. By prioritizing the needs of sellers and redistributing economic value, Sundae strives to become a leading buyer of homes that require significant attention across the United States.
Lendbuzz, Inc. is a car financing platform based in Boston, Massachusetts, established in 2015. It specializes in providing car loans to individuals with limited U.S. credit history, including international students, expats, and foreign professionals. The company utilizes machine learning algorithms and data-intensive scoring technology to assess creditworthiness based on factors such as employment, education, and personal history, rather than traditional credit scores or the requirement of a Social Security Number. This innovative approach allows Lendbuzz to offer attractive loan terms to customers who are often overlooked by conventional lenders. Once approved, clients can purchase vehicles from any dealership and work toward building their U.S. credit history while managing their loans through an online platform.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Cityblock Health, based in Brooklyn, New York, is a technology-driven healthcare provider focused on serving low-income urban communities with complex needs. Founded in 2017, the company aims to address the unmet health and social needs of Medicaid and Medicare populations through a personalized approach. Cityblock offers primary care, behavioral health, and virtual care services, emphasizing preventive care and mental health support. Its platform integrates communications and information sharing among care teams and members, facilitating better coordination of services. The company also collaborates with community-based organizations to enhance the delivery of care, ultimately seeking to improve health outcomes and reduce costs for its members.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Cityblock Health, based in Brooklyn, New York, is a technology-driven healthcare provider focused on serving low-income urban communities with complex needs. Founded in 2017, the company aims to address the unmet health and social needs of Medicaid and Medicare populations through a personalized approach. Cityblock offers primary care, behavioral health, and virtual care services, emphasizing preventive care and mental health support. Its platform integrates communications and information sharing among care teams and members, facilitating better coordination of services. The company also collaborates with community-based organizations to enhance the delivery of care, ultimately seeking to improve health outcomes and reduce costs for its members.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
The Trade Desk is a technology company that operates a self-service cloud-based platform designed for buyers of digital advertising. Established in 2009 and headquartered in Ventura, California, it enables advertising agencies and other service providers to create, manage, and optimize data-driven campaigns across various formats, including display, video, audio, native, and social media. The platform supports multiple devices, such as computers, mobile devices, and connected TVs. By leveraging data, The Trade Desk helps advertisers programmatically find and purchase digital ad inventory while optimizing the performance of their campaigns. The company's revenue model is primarily based on fees, which are calculated as a percentage of the advertising spend by its clients. With a global presence, The Trade Desk serves clients in the United States, Europe, and Asia, providing essential tools for digital media buyers.
Magic Leap is a US-based startup specializing in augmented reality (AR) technology that aims to transform user interaction with digital devices. The company develops a mixed reality computing platform that merges the digital and physical worlds through advanced three-dimensional imagery. Its proprietary headset utilizes Dynamic Digitized Lightfield Signal technology to create images that are indistinguishable from real objects, seamlessly integrating them into the user's environment. By combining users' natural visual capabilities with mobile computing, Magic Leap offers a unique AR experience that redefines how individuals engage with screens and visualize data. The system is designed to harmonize with human senses, allowing for an immersive and visually cinematic interaction with digital content.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Rubicon Global Holdings LLC is a technology company that specializes in cloud-based waste and recycling solutions for businesses, governments, and nonprofits. Founded in 2008 and headquartered in Atlanta, Georgia, Rubicon operates a digital marketplace and offers a suite of software-as-a-service products aimed at enhancing waste management and recycling efforts. The company provides various recycling programs, including services for cardboard, plastic, paper, metal, glass, electronics, and organics, as well as single stream recycling solutions. One of its notable offerings is RUBICONSmartCity, which assists municipal governments in optimizing waste and recycling operations while transforming their fleets into data collection centers to improve quality of life and government services through data analytics. Rubicon serves a global customer base and maintains core teams in several U.S. cities, including New York and San Francisco. The company is committed to driving environmental innovation and helping its partners achieve sustainability goals by finding economic value in waste streams.
TabbedOut puts you in control of your tab at bars and restaurants. Say goodbye to end-of-night bar lines, and flagging down your server when you’re ready to settle the bill. Never leave your card at the bar again! TabbedOut is easier and more secure than handing over your credit card to a stranger. Open a tab, view the running total, and pay for it instantly (and securely) all from your phone. You can even split your tab among friends, post to Facebook or Twitter to let your friends know where you’re dining, send a positive or negative review of your experience, and get offers sent from your favorite venue straight to your phone. TabbedOut takes the hassle out of dining out for good. We are adding new locations every day, so check in often on the locations screen. Don’t see your favorite bar or restaurant on the list? Let us know! Tweet at or Facebook us at @tabbedout. For merchants: TabbedOut is the premier marketing and analytics platform built exclusively for the hospitality industry and powered by mobile payments. We allow our merchants real time insight into their customers through our proprietary software system that tracks spending habits, product preferences, customer feedback and loyalty rewards. Best of all, TabbedOut allows you, the merchant, to accept mobile payments integrated into your POS system. Finally, POS systems and mobile payments meet customer marketing and rewards in real time. That’s the power of TabbedOut! Free to download and no hidden fees.
Harry's, Inc. is a consumer packaged goods company that specializes in manufacturing and selling shaving products and personal care items for men. Founded in 2012 and headquartered in New York, the company designs and produces its own line of razors, replacement blades, shaving creams, grooming kits, and face care products. Harry's operates an online platform that allows customers to purchase products a-la-carte or through a subscription model, facilitating convenient access to grooming essentials. By focusing on quality and affordability, Harry's aims to meet the needs of modern consumers seeking effective personal care solutions.
Oscar Health is a health insurance company that provides individual and family plans, Medicare Advantage, and small group products. Founded in 2012 and headquartered in New York, Oscar Health operates in several states, including New York, Texas, California, New Jersey, Ohio, and Tennessee. The company aims to enhance the healthcare experience by utilizing technology, design, and data to create user-friendly services. Its platform includes a software application that helps users find doctors based on location and ratings. Oscar Health primarily serves individuals and families who do not receive health insurance from their employers.
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.
The Honest Company is a consumer products company based in Santa Monica, California, founded in 2011. It specializes in designing and manufacturing eco-friendly and affordable products for babies and homes, focusing on three main categories: diapers and wipes, skin and personal care, and household and wellness items. The product range includes essentials such as eco-friendly diapers, bath and body products, cleaning supplies, and organic nutritional supplements, all available in customizable bundles for convenient online ordering and delivery. The company operates through a network of retail and digital channels, ensuring that its offerings are accessible to consumers across the United States. The Honest Company emphasizes purpose-driven products, catering to the needs of families while promoting sustainability.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online media companies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
Malauzai Software, Inc. is a software development company that specializes in mobile and Internet banking solutions tailored for community financial institutions such as banks and credit unions. Founded in 2009 and based in Austin, Texas, Malauzai offers a range of products including Consumer, Small Business, and Employee SmartApps, SmartwebApps, and SmartwearApps. These solutions are designed to enhance the customer experience by facilitating financial transactions through various devices, including wearable technology, smartphones, tablets, and desktops. The company's MOX enterprise platform serves as a SmartApp Management Infrastructure, effectively meeting the diverse needs of its users. Malauzai's Consumer product supports retail banking customers, while its Small Business product addresses the specific requirements of micro to medium-sized businesses. Additionally, the Employee product provides mobile tools for financial institution staff, improving both front-office and back-office operations. As of June 2018, Malauzai operates as a subsidiary of Finastra Group Holdings Limited.
SensAble Technologies, Inc. offers force-feedback haptic devices and touch-enabled 3D modeling software solutions. Its products include FreeForm Modeling Systems, which are 3D touch-enabled systems for medical and dental modeling, product design, digital content creation, and fine arts; and The SensAble Dental Lab System, a digital system for scanning, 3D modeling and design, and 3D fabrication. The company also provides PHANTOM Haptic Devices, which deliver force feedback, 3D navigation, and virtual workspaces; and OpenHaptics, a software development toolkit for developing haptic applications. In addition, it offers 3D touch-enabled modeling systems, software and devices, and 3D modeling software, and sculptural modeling for digital content creation and fine arts. SensAble Technologies serves academic/education, automotive/motorcycle, ceramics, characters and creatures, collectibles/giftware, confectionary, consumer products, dental, engraving, relief and flatware, facial reconstruction, film and video, fine arts and sculpture, footwear, games, home decor and housewares, jewelry, medical, packaging, personal care products, sporting goods, tooling, toys and promotional, assembly path planning, molecular modeling, simulation and visualization, and training industries. The company's products are used in product design, medical and dental modeling, digital content creation, fine arts applications, surgical simulation and stroke rehabilitation, dental restorations, and research and robotic applications. It offers its products through inside sales channels and resellers. The company was founded as SensAble Devices, Inc. in 1993 and changed its name to SensAble Technologies, Inc. in 1996. SensAble Technologies, Inc. is based in Woburn, Massachusetts with a sales office in Tokyo, Japan.